Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 8/20 | 1.00 |
| ▸ | SHBG | P04278 | 7/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 1.00 |
| ▸ | TSHR | P16473 | 5/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 4/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 4/20 | 1.00 |
| ▸ | PGR | P06401 | 3/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | ESR1 | P03372 | 2/20 | 1.00 |
| ▸ | THRB | P10828 | 1/20 | 1.00 |
| ▸ | AR | P10275 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.72 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.72 |
| ▸ | HTR2B | P41595 | 1/20 | 0.72 |
| ▸ | BLM | P54132 | 5/20 | 0.67 |
| ▸ | SERPINA6 | P08185 | 4/20 | 0.67 |
| ▸ | MAPT | P10636 | 3/20 | 0.67 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethisterone SCHEMBL7604035 | 1.00 | LMNA (1.00) | LMNASHBGSMN1; SMN2TSHRNR3C1 | |
| Ethisterone SCHEMBL606819 | 1.00 | LMNA (1.00) | LMNASHBGSMN1; SMN2TSHRNR3C1 | |
| Ethisterone SCHEMBL15581276 | 1.00 | LMNA (1.00) | LMNASHBGSMN1; SMN2TSHRNR3C1 | |
| Ethisterone SCHEMBL14433089 | 1.00 | LMNA (1.00) | LMNASHBGSMN1; SMN2TSHRNR3C1 | |
| Ethisterone SCHEMBL12417537 | 1.00 | LMNA (1.00) | LMNASHBGSMN1; SMN2TSHRNR3C1 | |
| Ethisterone SCHEMBL24475 | 1.00 | LMNA (1.00) | LMNASHBGSMN1; SMN2TSHRNR3C1 | |
| Ethisterone SCHEMBL16864523 | 1.00 | LMNA (1.00) | LMNASHBGSMN1; SMN2TSHRNR3C1 | |
| Ethisterone SCHEMBL16691330 | 1.00 | LMNA (1.00) | LMNASHBGSMN1; SMN2TSHRNR3C1 | |
| Ethisterone SCHEMBL28541256 | 0.99 | LMNA (0.98) | LMNASHBGSMN1; SMN2TSHRNR3C1 | |
| Ethisterone SCHEMBL11152514 | 0.96 | LMNA (0.92) | LMNASHBGSMN1; SMN2TSHRNR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1228083-A2 | THERAPEUTIC TREATMENT OF ANDROGEN RECEPTOR DRIVEN CONDITIONS | Hollis-Eden Pharmaceuticals Inc. (US) | 2002-08-07 | — | — | EP | claimed |
| WO-2001023405-A2 | THERAPEUTIC TREATMENT OF ANDROGEN RECEPTOR DRIVEN CONDITIONS | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2001-04-05 | — | — | WO | claimed |
| EP-0053845-B1 | 17-BETA-ETHYNYLSTEROIDS AND PROCESS FOR PREPARING SAME | MITSUBISHI KASEI CORPORATION (JP) | 1985-04-10 | — | — | EP | claimed |
| EP-0053845-A1 | 17-Beta-ethynylsteroids and process for preparing same | MITSUBISHI KASEI CORPORATION (JP) | 1982-06-16 | — | — | EP | claimed |
| US-4057542-A | Process for the preparation of 17β-hydroxy-3-oxo-17α-pregn-4-ene-21-carboxylic acid γ-lactone | G. D. SEARLE & CO. (US) | 1977-11-08 | — | — | US | claimed |
| US-4016270-A | Method for treating dysmenorrhea with a uterine therapeutic system | ALZA CORPORATION (US) | 1977-04-05 | — | — | US | claimed |
| US-4014988-A | Method for treating hypermenorrhea with uterine therapeutic system | ALZA CORPORATION (US) | 1977-03-29 | — | — | US | claimed |
| EP-2486924-B1 | Drugs and uses | NEURMEDIX INC (US) | 2018-12-26 | — | — | EP | disclosed |
| US-20130164780-A1 | Drug Identification Method | BIOVIE INC. | 2013-06-27 | — | — | US | disclosed |
| US-8367646-B2 | Steroid compounds and treatment methods | Harbor Therapeutics, Inc. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8354396-B2 | Identifying compounds that can treat autoimmune conditions; ulcerative colitis, inflammatory bowel disease, Crohn's disease, psoriasis, actinic keratosis, arthritis, multiple sclerosis, optic neuritis | Harbor Therapeutics, Inc. (US) | 2013-01-15 | — | — | US | disclosed |
| EP-2486924-A2 | Drugs and uses | Harbor BioSciences, Inc. (US) | 2012-08-15 | — | — | EP | disclosed |
| US-8217025-B2 | Utilizing such as 4-fluoro-17-ethynylandrost-5-ene-3-,7-,17-triol; pulmonary conditions, hyperglycemia, type 2 diabetes, insulin resistance | Harbor Therapeutics, Inc. (US) | 2012-07-10 | — | — | US | disclosed |
| US-4322349-A | Process for preparing 6-methylene steroids | SCHERING AKTIENGESELLSCHAFT (DE) | 1982-03-30 | — | — | US | disclosed |
| US-4179336-A | OXIDATIVE DEGRADATION OF ANDROSTANE STEROL 3-ACETAL | SCHERING AKTIENGELLSCHAFT (DE) | 1979-12-18 | — | — | US | disclosed |
| US-4170518-A | Microbiological conversion of sterol derivatives to 5-androsten-17-one derivatives and their use | SCHERING AKTIENGESELLSCHAFT (DE) | 1979-10-09 | — | — | US | disclosed |
| US-4057542-A | Process for the preparation of 17β-hydroxy-3-oxo-17α-pregn-4-ene-21-carboxylic acid γ-lactone | G. D. SEARLE & CO. (US) | 1977-11-08 | — | — | US | disclosed |
| US-4057542-A | Process for the preparation of 17β-hydroxy-3-oxo-17α-pregn-4-ene-21-carboxylic acid γ-lactone | G. D. SEARLE & CO. (US) | 1977-11-08 | — | — | US | disclosed |
| US-4016270-A | Method for treating dysmenorrhea with a uterine therapeutic system | ALZA CORPORATION (US) | 1977-04-05 | — | — | US | disclosed |
| US-4012497-A | Drug excipient of silicone rubber | SCHERING AKTIENGESELLSCHAFT (DT) | 1977-03-15 | — | — | US | disclosed |